GRFS Aug 2024 14.000 call
| Previous Close | 0.0300 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 14.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.0100 - 0.2800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.5k |
GlobeNewswireGrifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare systemThrough a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion)Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044Grifols will use al
- GlobeNewswire
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous immunoglobulins to meet strong demand Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest’s portfolio and is manufactured with an innovative process at Biotest’s new FDA-certified ‘Next Level’ facility U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin Lau
PR NewswireGrifols 2023 Annual Report on Form 20-F filed with the SEC
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").
